Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jun;12(6):317-8.
doi: 10.1038/nrneph.2016.58. Epub 2016 Apr 25.

Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer

David D Chism  1 , W Kimryn Rathmell  1
Affiliations
Comment

Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer

David D Chism et al. Nat Rev Nephrol. 2016 Jun.

Abstract

The first, highly anticipated randomized trial of adjuvant antiangiogenic therapy in renal cancer was recently reported. Although far from assuring, data from the adjuvant sorafenib or sunitinib for unfavorable renal carcinoma (ASSURE) trial offer a wealth of insights into the disease, treatments, and biological considerations for studies aimed at risk reduction.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Renal cell carcinoma (RCC) and Angiogenesis. The factors supporting micrometastatic disease, and early progression may be independent of the angiogenesis that high tumor burden metastatic disease requires for support. VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth factor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor.
See this image and copyright information in PMC

Comment on

References

    1. Coppin C, Kollmannsberger C, Le L, et al. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomized trials. BJU International. 2011;108(10):1556–1563. - PubMed
    1. Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet. doi: 10.1016/S0140-6736(16)00559-6. - DOI - PMC - PubMed
    1. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle. 2006;5(16):1779–87. - PubMed
    1. Allegra CJ, Yothers G, O’Connell MJ, et al. Bevacizumab in stage II–III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013;31:359–64. - PMC - PubMed
    1. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative beast cancer (BEATRICE): primary results of a randomized, phase 3 trial. Lancet Oncol. 2013;14(10):933–42. - PubMed

Publication types